[ad_1] The Phase 2 study will evaluate the efficacy, safety and tolerability of the company’s lead lipidated IL-22 analogue, CK-0045, in patients with obesity and type 2 diabetes COPENHAGEN, Denmark, Nov. 4, 2024 /PRNewswire/ — […]